首页 | 本学科首页   官方微博 | 高级检索  
     

白藜芦醇对裸鼠胶质瘤模型肿瘤生长的抑制作用
引用本文:胡 森 张 慧 步星耀 冯淼淼 王帮庆 王君毅 杨 斌 杨华超. 白藜芦醇对裸鼠胶质瘤模型肿瘤生长的抑制作用[J]. 中国临床神经外科杂志, 2019, 0(9): 543-546. DOI: 10.13798/j.issn.1009-153X.2019.09.010
作者姓名:胡 森 张 慧 步星耀 冯淼淼 王帮庆 王君毅 杨 斌 杨华超
作者单位:450046 郑州,河南中医药大学基础医学院(胡 森、王君毅、杨华超);450052 郑州,郑州大学第三附属医院康复科(张 慧);450052 郑州,河南省人民医院/郑州大学人民医院/河南大学人民医院神经外科(步星耀、冯淼淼、王帮庆、杨 斌)
摘    要:目的 探讨白藜芦醇(RES)不同途径给药对裸鼠胶质瘤模型肿瘤生长的抑制效果。方法 取80只雄性无胸腺裸鼠(BALB/c-nu;21~27日龄,体重10~12 g),采用U87细胞建立人裸鼠脑胶质瘤原位移植模型,采用随机数字表法分为RES干预组(造模后10 d,开始给药,1次/d,40 mg/kg)和溶剂对照组(造模后10 d,开始给药,1次/d,10 mg/kg;溶剂为0.5%羧甲基纤维素钠),根据给药途径,RES干预组又分为RES灌胃组和RES经鼻组,溶剂对照组又分为溶剂灌胃组和溶剂经鼻组,每组20只。经鼻给药采用经鼻滴入法。采用Kaplan-Meier法分析生存曲线;造模后14、21、28、35 d测定肿瘤体积;采用CD31标记胶质瘤血管内皮细胞并计算微血管密度(MVD),采用免疫组化方法检测胶质瘤血管内皮生长因子(VEGF)以及Ki-67表达,采用TUNEL法检测胶质瘤细胞凋亡。结果 与溶剂对照组相比,RES干预组裸鼠生存时间明显延长(P<0.05),造模后28、35 d肿瘤体积明显缩小(P<0.05),肿瘤组织MVD明显减小(P<0.05),肿瘤组织VEGF和Ki-67表达水平明显降低(P<0.05),肿瘤细胞凋亡率明显增加(P<0.05),而且,RES经鼻给药较灌胃给药作用更明显(P<0.05)。结论 RES可有效抑制裸鼠胶质瘤模型肿瘤生长,机制可能与抑制肿瘤血管生成和促进肿瘤细胞凋亡有关。与灌胃给药相比,经鼻给药肿瘤抑制效果更好。

关 键 词:胶质瘤  U87细胞  裸鼠胶质瘤模型  白藜芦醇  肿瘤生长  肿瘤血管生成  肿瘤细胞凋亡

Resveratrol inhibits tumor growth in nude mice model of glioma
HU Sen1,ZHANG Hui2,BU Xing-yao3,FENG Miao-miao3,WANG Bang-qing3,WANG Jun-yi1,YANG Bin3,YANG Hua-chao1. Resveratrol inhibits tumor growth in nude mice model of glioma[J]. Chinese Journal of Clinical Neurosurgery, 2019, 0(9): 543-546. DOI: 10.13798/j.issn.1009-153X.2019.09.010
Authors:HU Sen1  ZHANG Hui2  BU Xing-yao3  FENG Miao-miao3  WANG Bang-qing3  WANG Jun-yi1  YANG Bin3  YANG Hua-chao1
Affiliation:1. Basic Medical School, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China; 2. Department of Rehabilitation, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; 3. Department of Neursurgery, Henan Provin
Abstract:Objective To investigate the effect of resveratrol (RES) on tumor growth in nude mice model of glioma. Methods Eighty nude mice models of glioma were established by injection of U87 cells into the cerebral tissues, then these nude mice were randomly divided into RES intervention group (administration 10 days after injection of U87 cells, 40 mg/kg) and solvent control group (administration 10 days after injection of U87 cells, once a day, 10 mg/kg; the solvent was 0.5% sodium carboxymethyl cellulose). According to the route of administration, the RES intervention group was then divided into RES intragastric group and RES transnasal group, and the solvent control group was divided into solvent intragastric group and solvent transnasal group, with 20 mice in each group. The survival time was analyzed by Kaplan-Meier method, the tumor volume was measured at 14, 21, 28 and 35 days after injection of U87 cells, the microvessel density (MVD) was calculated by labeling the vascular endothelial cells with CD31, the expressions of vascular endothelial growth factor (VEGF) and Ki-67 were detcted by immunohistochemical staining, and the apoptosis of glioma cells was detected by TUNEL method. Results Compared with the solvent control group, the survival time of nude mice was significantly prolonged (P<0.05), the tumor volume was significantly reduced (P<0.05), the MVD of tumor tissue was significantly decreased (P<0.05), the expressions of VEGF and Ki-67 in tumor tissue was significantly decreased (P<0.05), and the apoptosis rate of tumor cells was significantly increased in RES intervention group (P<0.05). Moreover, the tumor inhibitory effect of RES by transnasal administration was significantly better than RES by intragastric administration (P<0.05). Conclusion RES can effectively inhibit the tumor growth in nude mice model of glioma, which may be related to the inhibition of tumor angiogenesis and the promotion of tumor cell apoptosis. Compared with the intragastric administration, transnasal administration of RES has better tumor inhibitory effect.
Keywords:Glioma   Resveratrol   Nude mice model of glioma   Tumor angiogenesis   Tumor growth   Tumor cell apoptosis
本文献已被 CNKI 等数据库收录!
点击此处可从《中国临床神经外科杂志》浏览原始摘要信息
点击此处可从《中国临床神经外科杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号